Cited by — Phase 1/2 study of favezelimab plus pembrolizumab in anti-PD-1-naive relapsed or refractory classical Hodgkin lymphoma | ResearchHub - ResearchHub
Research graph
Cited by
Admitted local publications that cite Phase 1/2 study of favezelimab plus pembrolizumab in anti-PD-1-naive relapsed or refractory classical Hodgkin lymphoma.
No admitted local citation edges point to this work yet.
